Skip to content

BioPlus Acquisition Corp.

Delisted

CIK 1856653fmd_15040BZ656H95VY8KRQBFJSBKZManufacturing · Electromedical & Electrotherapeutic ApparatusTemplate: Standard

Coverage: Apr 01, 2021 to Jun 30, 2023, 8 periods

Latest annual · FY2022

Millions
Operating income
(1)
Net income
2

Latest quarter · Q2 FY2023

Millions
Operating income
(1)
Net income
1
Open Financials

BioPlus Acquisition Corp. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2022ChangeSource
Operating income-$1.2 million10-K 2023-03-31 · proof
Net income$2 million10-K 2023-03-31 · proof
Cash from operating activities-$691,46510-K 2023-03-31 · proof
Total assets$238.3 million10-K 2023-03-31 · proof
Total liabilities$15.3 million10-K 2023-03-31 · proof
Cash and cash equivalents$140,30210-K 2023-03-31 · proof
What was BioPlus Acquisition Corp.'s operating income in fiscal 2022?
BioPlus Acquisition Corp. reported operating income of -$1.2 million for fiscal 2022 (the year ended Dec 31, 2022). Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
What was BioPlus Acquisition Corp.'s net income in fiscal 2022?
BioPlus Acquisition Corp. reported net income of $2 million for fiscal 2022 (the year ended Dec 31, 2022). Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
What was BioPlus Acquisition Corp.'s cash from operating activities in fiscal 2022?
BioPlus Acquisition Corp. reported cash from operating activities of -$691,465 for fiscal 2022 (the year ended Dec 31, 2022). Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
What are BioPlus Acquisition Corp.'s total assets?
As of Dec 31, 2022, BioPlus Acquisition Corp. reported total assets of $238.3 million. Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
What are BioPlus Acquisition Corp.'s total liabilities?
As of Dec 31, 2022, BioPlus Acquisition Corp. reported total liabilities of $15.3 million. Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
What are BioPlus Acquisition Corp.'s cash and cash equivalents?
As of Dec 31, 2022, BioPlus Acquisition Corp. reported cash and cash equivalents of $140,302. Source: the 10-K filed with the SEC on Mar 31, 2023. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1856653&period_type=annual&limit=5"

Information only, not investment advice.